In a pediatric cardiac arrest, the seconds spent calculating a weight-based adrenaline dose are seconds the patient cannot spare. The math is high-stress, and the margin for error is measured in micrograms per kilogram. RAPIDOSE, a medical device startup from Auckland, New Zealand, is betting that a dedicated, purpose-built tool can eliminate that calculation delay and its associated risk.
Founded in 2024, the company is developing a hardware device designed to deliver accurate, weight-based adrenaline dosing specifically for children in cardiac arrest [University of Auckland, Aug 2025]. The product, developed in collaboration with frontline healthcare providers, is described as easy to use, fast, and reliable [Prospeo]. For founder Adrian Ng and his early backers at Icehouse Ventures and Outset Ventures, the bet is that a focused piece of hardware can carve out a critical niche in emergency pediatric care [NZ Herald, 2026].
A Hardware Wedge in a High-Stakes Gap
The clinical problem RAPIDOSE is addressing is a failure of speed and precision under extreme pressure. Pediatric advanced life support protocols are clear on the need for weight-based epinephrine dosing, but in the chaos of a code, clinicians must either recall a formula, consult a reference chart, or rely on mental math. RAPIDOSE's device appears to function as a dedicated calculator and delivery aid, physically guiding the user to the correct dose based on a child's weight.
This approach represents a classic hardware wedge: solving one narrow, high-consequence problem exceptionally well. The company's focus on collaboration with frontline providers suggests an emphasis on real-world workflow integration.
The Path Through Regulation and Adoption
The ambition is clear, but the path forward for any new medical device is defined by regulatory hurdles and clinical validation. RAPIDOSE has not publicly disclosed its regulatory status, nor has it shared data from clinical trials. For a device intervening in a life-or-death scenario, regulatory approval is a fundamental prerequisite for use.
- Regulatory gate. The lack of public data on clinical trials or regulatory submissions remains the single largest uncertainty for the company's timeline and viability.
- Clinical integration. Success depends on convincing emergency departments to adopt a new piece of equipment and integrate it into high-stakes, team-based resuscitation protocols.
- Market focus. The extremely narrow focus on pediatric cardiac arrest limits the total addressable market but could create a defensible, mission-aligned niche.
The company's participation in the Outset Ventures accelerator and its undisclosed pre-seed funding provide runway to tackle these initial challenges [NZ Herald, 2026].
For the children and families affected by pediatric cardiac arrest, the standard of care today is a protocol reliant on human calculation and recall. Clinicians work from memory aids and Broselow tapes, converting a child's weight or length into a drug dose under immense time pressure. RAPIDOSE is placing its bet on that translation, aiming to build a device that makes the right dose the only dose a clinician can give.